The tissue diagnostic market has seen considerable growth due to a variety of factors.
• The market size for tissue diagnostics has seen a swift expansion in the recent past. It is predicted to rise from $5.77 billion in 2024 to $6.44 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 11.5%.
Factors contributing to this growth during the preceding period include an aging demographic, rising incidences of cancer, advances in technology, greater awareness of diseases, and improved efficiency in pathology workflows.
The tissue diagnostic market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the tissue diagnostic market is predicted to witness swift expansion. It is estimated to scale up to $10.67 billion by 2029 with a compound annual growth rate (CAGR) of 13.5%.
Factors contributing to the anticipated growth during this forecast period include the expansion of personalized medicine, the emergence of liquid biopsies, the adoption of AI and machine learning, the growth of telepathology, and the use of minimally invasive techniques. Main trends to watch out for during this forecast period involve digital pathology, the application of artificial intelligence (AI), telepathology services, multiplex staining and imaging, as well as the incorporation of genomic data.
The tissue diagnostic market is predicted to experience growth due to the escalating prevalence of cancer. Cancer originates when genetic alterations trigger rampant cell growth, attacking the body tissue and forming a tumorous mass, which can either be malignant or benign. The numerous causes of cancer comprise genetic deviations, carcinogens, obesity, smoking, radiation, hormones, and various others. The increasing instances of cancer necessitate the requirement for diagnostic methodologies such as tissue diagnostics to evaluate the condition. For example, the World Health Organization, a United Nations agency based in Switzerland, projected in February 2024 that the number of new cancer cases will exceed 35 million in 2050. With a 77% surge from the approximated 20 million cases in 2022, the escalating prevalence of cancer propels the expansion of the tissue diagnostic market.
The tissue diagnostic market covered in this report is segmented –
1) By Product: Consumables, Antibodies, Kits, Reagents, Probes, Instruments, Slide Staining System, Scanner, Tissue Processing system
2) By Technology: Immunohistochemistry (IHC), In Situ Hybridization (ISH), Digital Pathology And Workflow Management, Special Staining
3) By Disease: Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-Small Cell Lung Cancer (NSCLC)
4) By End User: Hospitals, Research Laboratories, Pharmaceutical Companies, Contract Research Organizations
Subsegments:
1) By Consumables: Biopsy Needles, Slides And Cover Slips, Tissue Embedding Materials
2) By Antibodies: Primary Antibodies, Secondary Antibodies, Monoclonal Antibodies, Polyclonal Antibodies
3) By Kits: Diagnostic Kits, Assay Kits, Staining Kits
4) By Reagents: Fixatives, Staining Reagents, Antigen Retrieval Solutions
5) By Probes: Fluorescent Probes, Molecular Probes, Hybridization Probes
6) By Instruments: Microscopes, Tissue Microarray Instruments, Laser Capture Microdissection Instruments
7) By Slide Staining System: Automated Stainers, Manual Staining Systems
8) By Scanner: Digital Slide Scanners, Whole Slide Imaging Systems
9) By Tissue Processing System: Tissue Processors, Embedding Centers, Microtomes
The increasing trend of product innovation is becoming prevalent in the tissue diagnostic market. This includes the emergence of novel products and solutions capable of gathering various types of samples, testing numerous samples at once, automating clinical laboratory procedures, and making them universally accessible. Dominant players are concentrating on devising and providing these automated tissue diagnostic mechanisms to gain an upper hand in the market and elevate their profits. For example, in June 2022, the Switzerland-based healthcare firm, Roche, unveiled the Benchmark ULTRA PLUS system for cancer diagnostics. The Benchmark ULTRA PLUS tissue staining system, enhancing workflow efficiency, testing capability, and environmentally friendly features, allows pathologists to deliver top-quality, time-sensitive results to medical practitioners and their patients. This advanced system features various innovative elements such as user-friendly software, remote monitoring functions, an in-built touchscreen for an enhanded user experience, and a more ecologically mindful waste system and product packaging.
Major companies operating in the tissue diagnostic market include:
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Agilent Technologies Inc.
• Merck KGaA
• BioGenex Laboratories
• Sakura Finetek Co. Ltd.
• Philips Healthcare NV
• Bio-Rad Laboratories
• Ventana Medical Systems Inc.
• Hologic Inc.
• Becton Dickinson and Company
• Sysmex Corporation
• Cell Signaling Technology Inc.
• Enzo Life Sciences Inc.
• Epitomics Inc.
• Fluidigm Corporation
• GE Healthcare Technologies Inc.
• Genomic Health Inc.
• Illumina Inc.
• Leica Microsystems GmbH
• Menarini Diagnostics S.r.l
• Myriad Genetics Inc.
• NanoString Technologies Inc.
• PerkinElmer Inc.
• QIAGEN N.V.
• Siemens Healthineers AG
• Zeiss Group AG
• CytomX Therapeutics Inc.
North America was the largest region in the tissue diagnostic market in 2024. The regions covered in the tissue diagnostic market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.